October 11, 2023
Israeli biotech startup Mana.bio launches AI-fueled programmable drug therapy
The company is employing AI to design lipid nanoparticles (LNPs) with the goal of creating programmable drug treatments
October 10, 2023
Exclusive: Andreessen Horowitz-backed startup is using AI to design lipid nanoparticles that go beyond the liver
One of the biggest challenges facing genetic medicines is getting them to the right part of the body. Little balls of fat called lipid nanoparticles used to carry mRNA can be injected into the arm for vaccines or infused into the blood to shuttle genetic medicines to the liver. But delivering the molecules to other cells or organs remains a challenge.
October 10, 2023
Mana.bio closes oversubscribed $19.5M seed funding
Mana.bio’s first-of-its-kind AI platform discovers and optimizes novel, customizable LNPs for tissue-specific delivery of nucleic acid-based therapeutics and vaccines, today announcing its seed funding
March 8, 2023
The Decade of RNA Delivery – Beyond the Liver
With the opportunity to treat spades of infectious diseases, cancers and single gene disorders, there is enormous potential in RNA therapeutics. To realize it, however, researchers will need to optimize delivery to on-target cells, minimize exposure to off-target cells and move beyond the liver.
January 1, 2023
Tech Founders, Don’t Be Afraid of Bio
Starting a TechBio company is a rewarding challenge. In this episode Yogev Debbi, Co-founder and CEO at Mana.bio enjoys discussing it with Omri Amirav-Drory from NFX, his co-founder from their first TechBio company Genome Compiler and now an investor at Mana.bio where we're disrupting Drug Delivery using ML/AI.
June 21, 2022
Mana.bio integrates CAS chemical substance data into its novel drug delivery AI platform
An agreement to embed chemical substance data from the CAS Content CollectionTM directly into the Mana.bio AI data acquisition workflow via an application programmable interface (API). This collaboration will enrich Mana.bio’s proprietary database to fuel its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.